Prince Edward Island College of Pharmacists
Regulating the practice of pharmacy in the province so as to promote a high standard and safeguard the welfare of the public with regard to pharmaceutical service.Useful Links
- Institute for Safe Medication Practices (ISMP)
- Canadian Pharmacists ASSOCIATION
- Canadian Society of Hospital Pharmacists
- Pharmacy Examining Board of Canada
- Canadian Association of Pharmacy Students and Interns
- Prince Edward Island Pharmacists Association
- National Association of Pharmacy Regulating Authorities
- Canadian Association of Pharmacy Technicians
Complaints and Discipline
NEWS & EVENTS
Jurisprudence Exam Sitting Dates
The spring sitting of the PEI Jurisprudence Exam will be held a the PEI College of Pharmacists office from 9:30-11:30 on June 10, 2016. The application for the exam can be found in the member home page of registered students and interns.
SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic Ketoacidosis
BICILLINL-A Injection (penicillin G benzathine) 2 mL Single Use Syringe - Shortage and Replacement with Australian Labelled Stock
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation
CellCept (mycophenolate mofetil) and MYFORTIC (mycophenolate sodium) - Serious Risk of Teratogenicity in Mycophenolate-Containing Products
Fourteen Health Products Manufactured by Hospira- Incorrect, Outdated or Missing Labelling Information
Alveda Atropine Injection BP 0.4 mg/mL - Recall of One Lot Due to the Same Barcode as Alveda Epinephrine Injection USP 1 mg/mL
Physicians, Hospitals, Hospital Pharmacists, Long Term Care Facilities, Paramedics/Emergency Services, Retail Pharmacies, Medical Clinics and Dentists.
BRAVELLE (75 IU urofollitropin for injection, purified) - Recalled lots due to Reduced Therapeutic Effect
Ferring Inc. Canada, in consultation with Health Canada, would like to inform health care professionals of a voluntary recall of four (4) lots of BRAVELLE. The recall is due to reduced potency of the product detected during routine stability testing.
The labels on the product and the package insert currently being distributed by Hospira do not reflect the most up-to-date information and warnings. The missing information and warnings may increase the risk to patients and may result in significant patient harm requiring medical intervention. Specifically, these warnings are detailed below: